Holen Sie sich die Stockscreener-App
20.07
2.29%
-0.47
Handel nachbörslich:
20.07
Schlusskurs vom Vortag:
$20.54
Offen:
$20.3
24-Stunden-Volumen:
124.76K
Relative Volume:
0.38
Marktkapitalisierung:
$332.78M
Einnahmen:
$99.61M
Nettoeinkommen (Verlust:
$-153.60M
KGV:
-1.2202
EPS:
-16.4479
Netto-Cashflow:
$-152.14M
1W Leistung:
-1.86%
1M Leistung:
-21.82%
6M Leistung:
-5.82%
1J Leistung:
+96.76%
1-Tages-Spanne:
$19.86
$20.43
1-Wochen-Bereich:
$19.46
$21.28
52-Wochen-Spanne:
$7.15
$43.85
Sutro Biopharma Inc Stock (STRO) Company Profile
Firmenname
Sutro Biopharma Inc
Sektor
Branche
Telefon
650-392-8412
Adresse
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare STRO vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
20.07 | 350.86M | 99.61M | -153.60M | -152.14M | -16.45 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-07 | Eingeleitet | Leerink Partners | Outperform |
| 2026-03-24 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2026-03-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-01-20 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-06-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-03-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-03-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-03-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-05-08 | Eingeleitet | BofA Securities | Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-06 | Eingeleitet | Oppenheimer | Outperform |
| 2023-03-21 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-06-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-09-02 | Eingeleitet | Jefferies | Buy |
| 2020-07-16 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-10-07 | Eingeleitet | BTIG Research | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2019-04-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-10-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2018-10-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-10-22 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Sutro Biopharma Inc Aktie (STRO) Neueste Nachrichten
Sutro Biopharma Stock Price Forecast. Should You Buy STRO? - StockInvest.us
A Quick Look at Today's Ratings for Sutro Biopharma(STRO.US), With a Forecast Between $49 to $56 - Moomoo
Mackay Gold & Silver: Mackay Gold & Silver Adds Second Drill Rig to Test the Historic Sutro Tunnel Intersection of the Occidental-Brunswick Lode at Depth, Comstock District, Nevada - FinanzNachrichten.de
Merck & Co. Inc. Invests $9.04 Billion in Sutro Biopharma, Inc. $STRO - MarketBeat
Sutro Biopharma (STRO) Climbs 2.91% as Shares Test Key Resistance at $22.12New Highs New Lows - vinanet.vn
Stifel Maintains Sutro Biopharma(STRO.US) With Buy Rating, Maintains Target Price $48 - Moomoo
Sutro Biopharma (STRO) Shares Slide 3.89% to $20.48 as Selling Pressure IntensifiesDealer Positioning - vinanet.vn
Broker Revenue Forecasts For Sutro Biopharma, Inc. (NASDAQ:STRO) Are Surging Higher - simplywall.st
Sutro Biopharma, Inc. (NASDAQ:STRO) Just Reported And Analysts Have Been Lifting Their Price Targets - simplywall.st
Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Rating of "Buy" by Analysts - MarketBeat
Sutro Biopharma (STRO): Perceptive Advisors reports 7.9% beneficial stake - Stock Titan
Sutro Biopharma (STRO): Point72 group reports 1.4% stake in 13G/A - Stock Titan
Sutro Biopharma Q3 EPS Forecast Reduced by HC Wainwright - MarketBeat
STRO Maintained by Citizens -- Price Target Lowered to $34.00 - GuruFocus
Sutro Biopharma (NASDAQ:STRO) Price Target Lowered to $34.00 at Citizens Jmp - MarketBeat
STRO Reiterated by Wedbush -- Price Target Maintained at $60 - GuruFocus
Truist Financial Maintains Sutro Biopharma(STRO.US) With Buy Rating, Announces Target Price $50 - Moomoo
Sutro Biopharma (NASDAQ:STRO) Earns Outperform Rating from Wedbush - MarketBeat
Citizens cuts Sutro Biopharma stock price target on revenue miss - Investing.com
Citizens cuts Sutro Biopharma stock price target on revenue miss By Investing.com - Investing.com Canada
Sutro Biopharma earnings missed by $0.13, revenue fell short of estimates - Investing.com Canada
Is Sutro Biopharma Inc (STRO) Facing Pressures After Q2 Earnings - GuruFocus
Sutro Biopharma Releases Q2 2026 Financial Results - AlphaStreet
Why is Sutro Biopharma Stock Falling On Wednesday? - TradingView
Sutro Biopharma (NASDAQ:STRO) Posts Quarterly Earnings Results, Misses Expectations By $0.14 EPS - MarketBeat
Sutro Biopharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Sutro Biopharma Reports Q2 2026 Financial Results and Pipeline Update - Kalkine Media
Sutro Biopharma Announces Q2 2026 Financial Results and Updates Corporate Presentation - Kalkine Media
Form 8K Sutro Biopharma For: 12 August By Investing.com - Investing.com Nigeria
Sutro Biopharma Q2 Results Highlight Advancing ADC Pipeline - TipRanks
Sutro reports early clinical responses from STRO-004 cancer trial By Investing.com - Investing.com Australia
SUTRO BIOPHARMA, INC. 2Q 2026: Revenue $9.84M, EPS ($2.33) — 10-Q Summary - TradingView
Sutro Biopharma (STRO) revenue drops as cash rises after $110M stock sale - Stock Titan
Sutro Biopharma Reports $9.8 Million Revenue in Q2 2026 - Quiver Quantitative
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study - The Manila Times
Sutro Biopharma delivers Q2 2026 financials and advances Phase 1 STRO-004 trial - Traders Union
Sutro Biopharma (STRO) Edges Higher to $25.53 as Traders Eye Key Resistance at $26.81Stock News - dars.gov.et
Stifel Initiates Sutro Biopharma(STRO.US) With Buy Rating, Announces Target Price $48 - moomoo.com
Sutro Biopharma (STRO) Institutional Ownership 2026 $STRO - MarketBeat
SUTRO BIOPHARMA INC : STIFEL INITIATES COVERAGE WITH BUY RATING; PRICE TARGET $48 - Bitget
Stifel initiates Sutro Biopharma stock with buy on ADC platform By Investing.com - Investing.com Australia
Stifel initiates Sutro Biopharma stock with buy on ADC platform - Investing.com
BlackRock, Inc. Adds to Sutro Biopharma Inc (STRO) Stake -- Shar - GuruFocus
Sutro Biopharma (STRO) Advances 3.85% to $25.10, Approaching Key ResistanceFloat Adjusted Cap - vinanet.vn
Perceptive Advisors LLC Invests $17.82 Million in Sutro Biopharma, Inc. $STRO - MarketBeat
Sutro Biopharma Inc (STRO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Sutro Biopharma (STRO) Surges as Volume Supports Bullish MomentumVolatility Breakout Picks - dars.gov.et
BlackRock, Inc. (NASDAQ: STRO) reports 6.4% ownership in Sutro Biopharma - Stock Titan
ADAR1 Capital Management LLC Purchases 457,364 Shares of Sutro Biopharma, Inc. $STRO - MarketBeat
Eversept Partners LP Trims Stake in Sutro Biopharma, Inc. $STRO - MarketBeat
Sutro Biopharma Inc (STRO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Finanzdaten der Sutro Biopharma Inc-Aktie (STRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sutro Biopharma Inc-Aktie (STRO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 04 '26 |
Option Exercise |
0.00 |
675 |
0 |
10,025 |
| Chung Jane | Chief Executive Officer |
Mar 04 '26 |
Option Exercise |
0.00 |
788 |
0 |
21,567 |
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 02 '26 |
Option Exercise |
0.00 |
2,356 |
0 |
10,320 |
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 01 '26 |
Option Exercise |
0.00 |
1,342 |
0 |
8,515 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Mar 02 '26 |
Option Exercise |
0.00 |
2,843 |
0 |
10,688 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Mar 01 '26 |
Option Exercise |
0.00 |
1,125 |
0 |
8,308 |
| Chung Jane | Chief Executive Officer |
Mar 02 '26 |
Option Exercise |
0.00 |
7,750 |
0 |
23,558 |
| Chung Jane | Chief Executive Officer |
Mar 01 '26 |
Option Exercise |
0.00 |
3,188 |
0 |
17,079 |
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):